Top Health Tech Companies in Dublin (80)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.
Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.
Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.
Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline...
Eirdoc Online Doctor: Your Convenient Gateway to Quality Healthcare. Experience the ease and accessibility of online healthcare with Eirdoc Online Doctor. Our team of experienced and qualified physicians is available to provide immediate GP consultations via video or telephone, ensuring that your health remains a top priority without disrupting your busy schedule.
At Sonder, we help organisations improve the wellbeing of their people and empower them to be at their best. We do this by providing leaders with a comprehensive care platform that delivers support through the right care, at the right time. Allowing people take control of their wellbeing in a way that suits them - on their terms, on their...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
The Avoca Clinic is Ireland’s leading Plastic Surgery Clinic for a reason. Located in multiple discrete locations around the country, you’ll immediately feel the warmth and luxury of our beautifully designed spaces that are home to some of the most technologically advanced equipment and world-class surgeons. Offering the very latest procedures and techniques available to the cosmetic surgery industry, we...
seamlessCARE Ltd. develops innovative assistive technologies that are grounded in years of health care, industry and academic research. Empathic app and API interprets the emotions of non-verbal people. This is the first of many technologies to enhance the lives of adults and children with complex needs.
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.
EPAM (NYSE:EPAM) is a global leader in AI transformation engineering and integrated consulting, serving Forbes Global 2000 companies and ambitious startups. With over thirty years of expertise in custom software, product and platform engineering, EPAM empowers organizations to become AI-Native enterprises, driving measurable value from innovation and digital investments. Recognized by industry benchmarks and leading analysts as a leader in...
EPAM Systems's Top Stability & Growth Strengths
Strong Market Position & Advantage: Analyst and client recognitions position EPAM as a leader in digital engineering and AI-enabled transformation, including multiple IDC MarketScape leadership placements and a Gartner recognition for custom software development. Independent coverage likewise describes the firm as a leading provider in these segments, reinforcing a durable competitive footing.
Resilient & Sustainable Growth: Revenue continues to expand year over year in recent quarters and on a trailing-twelve-month basis, and management still guides to growth for the current year despite a tougher backdrop. The pace has moderated compared with the prior year, but the trajectory remains positive.
Innovation-Driven Growth: The company is leaning into AI-native services and is identified as a leader in AI transformation engineering alongside strengths in data modernization and software engineering. This innovation-led mix is presented as a key engine for future expansion.
The Wellola team believes only the sickest of the sick should be hospitalised and that the future of healthcare is preventative, community-based and supported by digital tools. Wellola prides itself in being highly user-focused, reliable, robust and easy-to-use. Our team have unique, in-depth sector know-how, our pricing model is extremely cost effective and our business model is scalable for national...
Medserv are the leading provider of medical billing and practice management services to consultants, consultant groups and hospitals throughout Ireland and the UK. Our innovative Smartphone App allows consultants to quickly and securely send us patient information, whilst also keeping track of your claims and payments. Medserv strives to improve the management of your private practice through: - Reducing your practice administration -...
At Fitbit, we created an entire industry around wearable technology with software and services to help people transform their lives for the better, from the smallest milestones to the biggest changes. 10k steps started out as a magic number and became an anthem for setting goals—but today, we take the Fitbit community well beyond it. Our global teams are on...
Webdoctor.ie is Ireland’s award-winning online GP service. As featured in Deloitte’s Fast 50 Technology Awards, Webdoctor.ie is an Irish-owned health technology platform founded and led by healthcare professionals. With 40+ Irish Medical Council registered doctors on its team, Webdoctor.ie can be accessed from anywhere in Ireland with an internet connection on a phone, tablet or computer via the website or...
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
At Vertigenius™️, we're pioneering the integration of technology and healthcare to address vestibular disorders, improving balance and reducing dizziness. Our innovative approach includes a clinician portal, a patient app, and a wearable head sensor, making rehabilitation accessible and efficient.
Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in...
Ipsen's Top Stability & Growth Strengths
Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.
Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.
Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.
MEG is a healthcare digital quality management system, used by healthcare providers in 15+ countries to simplify and streamline time-consuming care quality, patient safety, and accreditation processes across their organisations. Tools for audit, incident, risk, action planning, complaints, feedback surveys and documents and reporting are all conveniently managed on any device from one central location. Save time, gain real-time reporting...
Thrive's mission is to unlock human potential by ending the stress and burnout epidemic. We offer companies and individuals sustainable, science-based solutions to enhance both mental and physical well-being and performance, purpose and relationship with technology. We are committed to accelerating this culture shift around the world. This page is meant to be a safe place for honest, respectful conversation, and...
